Versor Investments LP Makes New $162,000 Investment in Certara, Inc. (NASDAQ:CERT)

Versor Investments LP purchased a new position in Certara, Inc. (NASDAQ:CERT) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,800 shares of the company’s stock, valued at approximately $162,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. TimesSquare Capital Management LLC boosted its position in shares of Certara by 3.1% during the 3rd quarter. TimesSquare Capital Management LLC now owns 956,655 shares of the company’s stock valued at $11,202,000 after acquiring an additional 29,090 shares during the last quarter. Atria Investments Inc boosted its position in shares of Certara by 21.6% during the 3rd quarter. Atria Investments Inc now owns 19,743 shares of the company’s stock valued at $231,000 after acquiring an additional 3,501 shares during the last quarter. Harbor Capital Advisors Inc. boosted its position in shares of Certara by 18.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 20,144 shares of the company’s stock valued at $236,000 after acquiring an additional 3,136 shares during the last quarter. Everence Capital Management Inc. boosted its position in shares of Certara by 21.0% during the 3rd quarter. Everence Capital Management Inc. now owns 14,910 shares of the company’s stock valued at $175,000 after acquiring an additional 2,590 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in shares of Certara by 112.3% during the 3rd quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock valued at $46,000 after acquiring an additional 2,076 shares during the last quarter. 73.96% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

CERT has been the subject of a number of research reports. Robert W. Baird lowered their target price on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Barclays decreased their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Finally, UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Certara presently has a consensus rating of “Hold” and an average target price of $15.92.

Certara Stock Performance

CERT stock opened at $9.96 on Monday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The business’s fifty day simple moving average is $10.90 and its two-hundred day simple moving average is $13.43. Certara, Inc. has a twelve month low of $9.88 and a twelve month high of $19.87. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -49.80, a PEG ratio of 5.04 and a beta of 1.51.

Certara (NASDAQ:CERT) last released its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. During the same quarter last year, the firm posted $0.06 earnings per share. The business’s revenue was up 10.7% compared to the same quarter last year. Analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. This represents a 33.94 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.